Stocks That Breached 52-Week Lows Today
Stocks That Managed to Breach 52-Week Lows Tuesday Morning
Before 10 am Tuesday, 44 stocks made new 52-week lows.
52-Week High And Low Highlights:
Block (NYSE: SQ) was the biggest company on a market cap basis to set aStocks That Managed to Breach 52-Week Lows Tuesday Morning
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year.
Space Stocks That Went Public In 2021 Fail To Launch, With One Exception
The international space race is heating up, and a wave of new space stocks hit the public market in 2021. Unfortunately for investors, the share prices of all but one of those space stocks are suffering from a major failure to launch.
12 Industrials Stocks Moving In Thursday’s After-Market Session
Gainers
ABM Indus (NYSE:ABM) shares rose 2.2% to $41.44 during Thursday's after-market session. This security traded at a volume of 51.0K shares come close, making up 14.3% of its average volume over the last 100 days. The company's market cap stands at $2.7 billion.
11 Industrials Stocks Moving In Monday’s After-Market Session
Gainers
Ideal Power (NASDAQ:IPWR) stock increased by 4.87% to $10.33 during Monday's after-market session. The market value of their outstanding shares is at $60.8 million.
10 Industrials Stocks Moving In Tuesday’s After-Market Session
Gainers
Energy Focus (NASDAQ:EFOI) stock moved upwards by 3.98% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $18.5 million.
58 Biggest Movers From Friday
Gainers
Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62.
TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30.
41 Stocks Moving In Friday’s Mid-Day Session
Gainers
IO Biotech, Inc. (NASDAQ: IOBT) jumped 42% to $11.74. The company, last month, priced its IPO at $14 per share.
56 Biggest Movers From Yesterday
Gainers
Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).